Cytonet GmbH & Co. KG, of Weinheim, Germany, said interim data on its liver cell therapy treatment presented at the Society for Inherited Metabolic Disorders meeting in Pacific Grove, Calif., showed that pediatric patients with urea cycle disorders (UCDs) treated with the therapy had advantages in parameters such as event-free survival time or incidence of moderate or severe hyperammonemic events. Read More
Ventana Medical Systems Inc., of Tucson, Ariz., a member of the Roche Group, said it inked a multiyear deal with Bayer AG, of Leverkusen, Germany, to develop companion diagnostics, with a focus on immunohistochemistry, across Bayer’s portfolio of targeted therapy projects. Read More
Ambry Genetics Inc., of Aliso Viejo, Calif., defended itself against the preliminary injunction motion filed on July 9, 2013, by Myriad Genetics Inc., of Salt Lake City, and other plaintiffs in University of Utah Research Foundation et al. v. Ambry Genetics Corp. Read More
Marina Biotech Inc., of Boston, closed its issuance of series C convertible preferred stock and common stock purchase warrants for gross proceeds of $6 million. Read More
The EMA published the first summary for the public of the risk-management plan (RMP) of a newly authorized drug. The summary describes what is known and not known about the safety of Mumbai, India-based Piramal Imaging SA’s Neuraceq (florbetaben) and what measures will be taken to prevent or minimize the risks of the radiopharmaceutical used in brain scans. Read More
SHANGHAI – After a year of revisions, China’s Ministry of Commerce (MOFCOM) revealed its anticipated new “simple rules” for mergers and acquisitions. The move signals the government’s intentions toward fast-tracking deals that don’t trigger competition issues, but with the caveat that certain conditions apply. Read More
Racing ahead of Congress, the Centers for Medicare & Medicaid Services (CMS) withdrew parts of a controversial rule revising the Medicare Part D prescription drug program. Read More
Five months after an upsized follow-on offering brought in $120 million and in the midst of preparing its new drug application (NDA) to the FDA for ATX-101, Kythera Biopharmaceuticals Inc. pulled off a crafty reacquisition of global rights for the aesthetic candidate from Bayer Healthcare’s Consumer Care Division, a unit of Bayer AG, of Leverkusen, Germany. Read More
The higher-dose glitch in otherwise strong phase II results with its galectin-3-targeting chronic kidney disease (CKD) therapy did little to hold back shares of La Jolla Pharmaceutical Co. (NASDAQ:LJPC), which closed Tuesday at $17.96, up $7.06, or 64.8 percent. Read More
